Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...

Gene Therapy

Gene Therapy

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Meta-analysis of adverse events in clinical studies with antisense oligonucleotide therapies.

Molecular therapy. Nucleic acids·2026

Same author

The extracellular matrix as a central regulator of aging and tissue adaptation to exercise.

American journal of physiology. Cell physiology·2026

Same author

N-acetylcysteine exerts senescence-selective antifibrotic effects in fibroblast from chronic wounds in Recessive Dystrophic Epidermolysis Bullosa.

The British journal of dermatology·2026

Same author

Generation of high-expressing transposon-based stable pools to produce (1 + 1) and (2 + 1) bispecific common light chain antibodies.

Biotechnology progress·2026

Same author

A guide to effective drug development through nonprofit models.

Nature reviews. Drug discovery·2026

Same author

Guidance on communication and informed consent with patients and their families for experimental individualized treatments.

American journal of human genetics·2026

Search research articles

Related Experiment Video

Updated: Mar 18, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

RNA-based therapies for genodermatoses.

Olivier Bornert¹, Patricia Peking², Jeroen Bremer³

¹Department of Dermatology, Medical Center - University of Freiburg, Freiburg, Germany.

Experimental Dermatology

|July 5, 2016

Summary

This summary is machine-generated.

RNA-based therapies offer new hope for genodermatoses (genetic skin disorders). This review details RNA splicing modulation, transcript replacement, and gene knockdown strategies, exploring their potential and challenges for improved patient treatment.

Keywords:

RNA trans-splicing antisense oligonucleotides in vitro-transcribed mRNA siRNA skin

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Mar 18, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Area of Science:

Dermatology
Genetics
Molecular Biology
RNA Therapeutics

Background:

Genodermatoses are a diverse group of genetic skin diseases with limited treatment options, often focusing on symptom management.
Current treatments for genodermatoses primarily address symptoms rather than the underlying genetic cause.
The development of targeted therapies is crucial for improving patient outcomes in genodermatoses.

Purpose of the Study:

To review the current landscape of RNA-based therapeutic strategies for genodermatoses.
To critically evaluate the opportunities, limitations, and challenges of emerging RNA-based treatments.
To provide a foundation for developing novel and improved therapies for genetic skin disorders.

Main Methods:

Review of RNA splicing modulation using antisense oligonucleotides.
Discussion of RNA trans-splicing and transcript replacement via in vitro-transcribed messenger RNAs (mRNAs).
Analysis of gene knockdown techniques employing small interfering RNA (siRNA) and antisense oligonucleotides.

Main Results:

RNA-based therapies, including antisense oligonucleotides, mRNA-based approaches, and gene knockdown, show significant promise for treating genodermatoses.
These advanced therapeutic modalities offer potential for addressing the root genetic causes of skin disorders.
The review highlights the current status and ongoing advancements in RNA-based therapeutic development for genetic skin diseases.

Conclusions:

RNA-based therapies represent a powerful emerging tool for genodermatoses, moving beyond symptom management.
Further research and development are necessary to overcome existing limitations and challenges in implementing these therapies.
The ultimate goal is to establish more effective treatments to enhance the quality of life for individuals affected by genodermatoses.